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Abstract   The first Ebolavirus diseases outbreak was in Zaire (now Democratic Republic of the Congo) in 1976. 
The 2014 Ebola outbreak is the deadliest and the largest Ebola outbreak in history and the first in western Africa. 
More than 2,746 people had died from this outbreak. The disease is a severe, often fatal in humans and nonhuman 
primates. It cannot naturally transmit through the air, water or food and can be spread by direct contact with blood 
and secretions of the infected patients. At present there is no standard treatment for Ebolavirus diseases; only 
supportive therapy is available. Hence prevention is the best way by not traveling to areas where the virus is found. 
The paper represents an elementary idea of Ebolavirus diseases to create consciousness of the disease among 
common people.    
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1. Introduction 
      Ebolavirus disease (EVD) or Ebola hemorrhagic 
fever (EHF) is a viral human disease caused by the 
Ebolavirus that results in nonspecific symptoms early 
in the disease and often causes internal and external 
bleedings as the disease progresses. Ebola 
hemorrhagic fever is considered one of the most 
lethal viral infections and the mortality rate is very 
high during outbreaks. Since 1976 EVD outbreaks 
have appeared sporadically in central and western 
Africa, for example, in Gabon, The Democratic 
Republic of the Congo (DRC), Sudan, The Ivory 
Coast, Uganda, Guinea, Sierra Leone, Nigeria and 
Liberia. There have been 26 confirmed outbreaks of 
the disease since 1976.  
    2014 Ebola outbreak has spread like wildfire and 
causes an alarming worldwide. The first cases were 
reported from Guéckédou, a forested region of south-
eastern Guinea near the border with Liberia and 
Sierra Leone. It is considered the deadliest and the 
largest Ebola outbreak in history and the first in 
western Africa [11]. 
    On 8 August 2014, the EVD outbreak in western 
Africa was declared in Geneva by the WHO to be a 
‘Public Health Emergency of International Concern 
(PHEIC)’, because it was determined to be an 
‘extraordinary event’ with public health risks to other 
States. After discussion and deliberation on the 
information provided, the committee advised that 
[46]: 
 The Ebola outbreak in western Africa 
constitutes an ‘extraordinary event’ and a 
public health risk to other States. 
 The possible consequences of further 
international spread are particularly serious 
in view of the virulence of the virus, the 
intensive community and health facility 
transmission patterns, and the weak health 
systems in the currently affected and most 
at-risk countries.  
 A coordinated international response is 
deemed essential to stop and reverse the 
international spread of Ebola.  
 
 
 
Figure 1: Ebola cases and deaths in 2014 outbreak. 
Source: [51].   
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    EVD can spread from country to country when 
people travel. The disease infections can only be 
confirmed through laboratory testing. 
    On 17 September 2014, WHO expressed that more 
than 2,746 people had died and 5,762 confirmed or 
probable cases in West Africa’s 2014 Ebola outbreak 
(figure 1). WHO also warned that at least $600 
million is needed to fight the virus, and more than 
20,000 people could be infected before the outbreak 
is brought under control [50]. 
 
2. Types of the Ebolavirus 
     It is a severe, often fatal disease in humans and 
nonhuman primates, such as monkeys, gorillas, and 
chimpanzees. Sometimes EVD affects in domestic 
pigs. EHF is caused by infection with a virus of the 
family Filoviridae, genus Ebolavirus. There are 5 
identified subspecies of Ebolavirus. Four of the 5 
subspecies i) Ebolavirus (Zaire ebolavirus), EBOV 
ii) Sudan virus (Sudan ebolavirus), SUDV, iii) 
Bundibugyo virus (Bundibugyo ebolavirus), BDBV 
and iv) Taï Forest virus (Taï Forest ebolavirus), 
TAFV, have caused disease in humans. The 5th 
Reston virus (Reston ebolavirus), has caused disease 
in nonhuman primates, but not in humans [10].  
     First three ebolavirus have been associated with 
large Ebolavirus disease outbreaks in Africa, whereas 
4th has not. Among the 5 subspecies Zaire ebolavirus 
is the most dangerous because it has the highest case 
fatality rate up to 90% [24]. Sudan ebolavirus is 
believed to have broken out first among cotton 
factory workers in Nzara, south Sudan in 1976 with 
fatality rates 50% to 68% [17]. Taï Forest ebolavirus 
was first discovered among chimpanzees from the 
Taï Forest in Ivory Coast, Africa, in 1994 [39]. On 24 
November 2007, the Uganda Ministry of Health 
confirmed an outbreak of Bundibugyo ebolavirus in 
the Bundibugyo district [42]. Reston ebolavirus 
discovered in Reston, Virginia and it has been found 
in nonhuman primates in Pennsylvania, Texas and 
Siena, Italy [7].   
 
3. History of Ebolavirus 
      The first Ebolavirus species were discovered in 
Sudan and the Democratic Republic of the Congo 
(DRC) near the tributary Ebola River valley (in the 
northern Congo basin of central Africa) during an 
outbreak in Zaire in 1976 [6]. Since 1976 the 
mortality rates varied from 50 to 90% (table 1). It is 
not clear why some patients can survive and others 
die from this disease, but patients who die usually 
have a poor immune response to the virus. The 
natural host for Ebolavirus is yet unknown. At 
present there is no antiviral therapy or vaccine that is 
effective against Ebolavirus infection in humans. 
Hence it has not been possible to implement skillful 
techniques to control or eliminate the disease at 
present situation [36].  
      The first outbreak of Ebola-Sudan infected in 
Sudan from June to November 1976. More than 284 
people (213 in Maridi, 67 in Nzara, 3 in Tembura and 
1 in Juba), with a mortality rate of 53% [40]. A few 
months later (September to October), the second 
Ebolavirus (Ebola-Zaire) emerged from Yambuku 
and northern Zaire, with the highest mortality rate of 
any of the Ebolaviruses (88%), infected 318 people 
[41]. In 1979 between 30 July and 7 October 34 cases 
of EVD (with 22 fatal) occurred among 5 families in 
rural district of southern Sudan.  Between 2 to 5 
August a family of 4 members in Nzara is infected 
with EVD but after admission in hospital all died. In 
the late August a second family of 20 members with 
EVD was admitted in hospital but 13 members of that 
family with 2 nurses who took care of them died. A 
total 5 families were infected with EVD between 30 
July and 7 October, 1979 [1]. 
     The Ebolavirus (Ebola Reston) was first identified 
in 1989 when infected monkeys were imported into 
Reston and Virginia of the USA to research facilities, 
from Mindanao in the Philippines, very few people 
who were infected with this virus and never 
developed EHF [22]. The Ebolavirus (Ebola Cote 
d’Ivoire) was discovered in 1994 when a female 
ethologist performing an autopsy on a dead 
chimpanzee from the Tai Forest, Cote d’Ivoire, 
accidentally infected herself during the autopsy [33].  
     The first outbreak of EHF due to Bundibugyo 
ebolavirus occurred in Uganda from August to 
December 2007. About 131 EHF cases (44 suspects, 
31 probable and 56 confirmed) are identified and 39 
died in that outbreak [25, 42]. 
      Most outbreaks of the lethal strains of Ebola have 
occurred in Africa and mainly in small- or medium-
sized towns. The largest outbreak to date is the 
ongoing “2014 western Africa Ebola outbreak”, 
which is affecting four countries Guinea, Liberia, 
Sierra Leone and Nigeria. More than 2,746 people 
had died in 2014 outbreak (table 1). The 2014 
outbreak becomes complicated by a limited health 
workforce and particularly by misperceptions of the 
disease among some people living in affected regions 
[9, 50].  
 
4. Symptoms of EVD 
      Common symptoms of Ebolavirus are; fever, 
myalgia, malaise, sore throat, weakness, severe 
headache, joint and muscle pain, diarrohea, vomiting, 
stomach pain, dehydration, dry and hacking cough, 
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lack of appetite. Symptoms of Ebolavirus typically 
start two days to three weeks after contacting the  
 
Table 1: EVD outbreaks since 1976. 
 
Year Virus Geographic Location Human 
Deaths 
Cases CFR (case-
fatality risk) 
1976 SUDV Juba, Madrid, Nzara, and Tembura,  Sudan  151 284 53% 
1976 EBOV Yambuku, Zaire 280 318 88% 
1977 EBOV Bonduni, Zaire  1 1 100% 
1979 SUDV Nzara, Sudan 22 34 65% 
1988 EBOV Porton Down, United Kingdom [laboratory 
accident] 
0 1 0% 
1994 TAFV Tai National Park, Cote d’Ivoire  0 1 0% 
1994–
1995 
EBOV Woleu-Ntem and Ogooue-Ivindo Provinces, 
Gabon  
32 52 62% 
1995 EBOV Kikwit, Zaire 245 317 77% 
1996 EBOV Mayibout 2, Gabon 21 31 68% 
1996 EBOV Sergiyev Posad, Russia [laboratory accident] 1 1 100% 
1996–
1997 
EBOV Ogooue-Ivindo Provinces, Gabon; Cuvette-
Ouest Department, Republic of the Congo  
46 62 74% 
2000–
2001 
SUDV Guku, Mbarara, and Masindi Districts, Uganda  224 425 53% 
2001–
2002 
EBOV Ogooue-Ivindo Provinces, Gabon; Cuvette-
Ouest Department, Republic of the Congo 
97 124 78% 
2002 EBOV Ogooue-Ivindo Provinces, Gabon; Cuvette-
Ouest Department, Republic of the Congo 
10 11 91% 
2002–
2003 
EBOV Cuvette-Ouest Department, Republic of the 
Congo; Ogooue-Ivindo Provinces, Gabon 
128 143 90% 
2003–
2004 
EBOV Cuvette-Ouest Department, Republic of the 
Congo 
29 35 83% 
2004 EBOV Koltsovo, Russia [laboratory accident] 1 1 100% 
2004 SUDV Yambio County, Sudan  7 17 41% 
2005 EBOV Cuvette-Ouest Department, Republic of the 
Congo 
9 11 82% 
2007 EBOV Kasai Occidental Province, Democratic 
Republic of the Congo  
186 264 71% 
2007–
2008 
BDBV Bundibugyo District, Uganda 39 116 34% 
2008–
2009 
EBOV Kasai Occidental Province, Democratic 
Republic of the Congo 
15 32 47% 
2011 SUDV Luweero District, Uganda 1 1 100% 
2012 SUDV Kibaale District, Western Uganda 17 24 71% 
2012 BDBV Orientale Province, Democratic Republic of the 
Congo 
36 77 47% 
2014 EBOV Guinea, Sierra Leone, Liberia, Nigeria 2,746 5,762 47.7% 
 
virus. After 4 to 6 days, on average, Ebola symptoms 
can begin. More cases Ebolavirus infection runs its 
course within 14 to 21 days. The period between 
infection with the virus and the start of symptoms is 
called the incubation period [7]. 
      After the infection progresses, patients experience 
severe bleeding and coagulation abnormalities, such 
as, gastrointestinal bleeding, rash, and a range of 
hematological irregularities, such as lymphopenia 
and neutrophilia. In the next step the virus damages 
the liver and impaired kidney and liver functions. 
Massive viremia is visible which leads to dispersed 
intravascular coagulopathy. Finally the Ebolavirus 
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infects microvascular endothelial cells and 
compromises vascular integrity [14]. 
     Some patients may experience rash, cough, red 
eyes, hiccups, chest pain, difficulty breathing, 
difficulty swallowing, internal and external 
bleedings, along with decreased functioning of the 
liver and kidneys.  At this point, some people begin 
to have problems with bleeding inside and outside of 
the body. At the end state, the patients feel delirium, 
shock, seizures and coma, causes levels of blood-
clotting cells to drop and finally died [44].   
     The patient fortunate enough to survive EHF still 
may have complications that may take many months 
to resolve. Survivors may experience weakness, 
fatigue, headaches, hair loss, hepatitis, sensory 
changes, and inflammation of organs. Death usually 
occurs during the 2nd week of symptoms and is 
usually from massive blood loss. In pregnant women, 
abortion and heavy vaginal bleeding are common 
Ebola symptoms [10]. 
 
5. Transmission of Ebolavirus 
      From the outbreaks since 1976, it is observed that 
Ebolavirus cannot naturally transmit through the air, 
water or food. A person who has Ebola but has no 
symptoms cannot spread the disease. Ebolavirus can 
be spread by direct contact with blood and secretions 
(stool, urine, saliva, semen etc.) that remain on 
clothing, tissues, organs or other bodily fluids of dead 
or living infected persons and by syringes used to 
treat Ebola-infected patients. Those who take care of 
a sick person or bury someone who has died from the 
disease often get it. Men who have recovered from 
the disease can still transmit the virus through their 
semen for as long as 7 weeks after recovery from 
illness. Unsanitary conditions and lack of adequate 
medical supplies may cause the spread of the disease 
[15]. 
     Health workers may be infected to the virus when 
caring for Ebola patients if they are not wearing 
personal protection equipment, such as gloves, when 
caring for the patients. In traditional burial 
ceremonies mourners come in direct contact with the 
dead body and can transmits the dieses [14]. 
    The disease may be acquired upon contact with the 
skin or blood or bodily fluids of an infected animal, 
such as monkeys, gorillas, forest antelopes, 
chimpanzees or fruit bats and porcupines found ill or 
dead. Fruit bats are believed to carry and spread the 
virus without being affected i.e., the natural host for 
the virus. Particularly species of the fruit bats 
Hypsignathus monstrosus, Epomops franqueti and 
Myonycteris torquata, are considered possible natural 
hosts for Ebolavirus. If actually fruit bats are natural 
hosts for Ebolavirus then the geographic distribution 
of Ebolaviruses may overlap with the range of the 
fruit bats [47]. 
    Reston ebolavirus has caused severe EVD 
outbreaks in macaque monkeys (Macaca 
fascicularis) farmed in Philippines and detected in 
monkeys imported into the USA in 1989, 1990 and 
1996, and in monkeys imported to Italy from 
Philippines in 1992. Since 2008, Reston ebolavirus 
has been detected during several outbreaks of a 
deadly disease in pigs in People’s Republic of China 
and Philippines [33]. 
     It is not known yet how the viruses attack cells; it 
has been postulated that they produce proteins that 
suppress the immune system, allowing reproduction 
of virus to continue unrestricted. Eating of bushmeat 
of wild animals, including hoofed animals, primates 
and rodents are another cause of transmission of 
EVD [15]. 
     However, Ebolavirus can be inactivated by ultra 
violate (UV) radiation, gamma irradiation, heating 
for 60 minutes at 60°C or boiling for 5 minutes. The 
virus is susceptible to sodium hypochlorite and 
disinfectants [31]. But it cannot be inactivated by 
freezing [13].  
 
6. Structure of Ebolavirus 
     Ebolavirus is pleomorphic, negative-sense RNA 
(ribonucleic acid) whose genome organization is 
most similar to the Paramyxoviridae. The Zaire 
ebolavirus genome is 19 kb long, with 7 open reading 
frames encoding structural proteins are: NP, VP35, 
VP40, GP, VP30, VP24 and L [30, 34].    
     The nucleoprotein (NP) is associated with the 
viral genome and assembles into a helical 
nucleocapside (NC) along with the polymerase 
cofactor (VP35), the transcription activator (VP30), 
and the RNA dependent RNA polymerase (L). The 
viral proteins that comprise the NC catalyze the 
replication and transcription of the viral genome [3, 
28, 29]. A minor viral matrix protein, VP24 is needed 
for NC assembly [27]. When NP is co-expressed with 
VP24 and VP35, NC-like structures are formed in the 
cytoplasm which is morphologically identical from 
those seen in infected cells [4, 5]. 
     The GP open reading frame of Ebolavirus gives 
rise to two gene products, a soluble 60–70 kDa 
protein and a full length 150–170 kDa protein that 
inserts into the viral membrane [37]. The Ebolavirus 
GP is synthesized in a secreted or full length 
transmembrane form, and each gene product has 
distinct biochemical and biological properties [35]. 
The Ebolavirus GP contains a homologous hairpin 
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structure so that a possible inhibitory peptide has 
been identified [38]. 
       Electron micrographs of Ebolavirus show them 
to have the characteristic threadlike structure of a 
filovirus, VP30 is around 288 amino acids long 
(figure 2). The virions are tubular in general form but 
 
 
Figure 2: Electron micrograph of an Ebolavirus 
viron. Source: [51]. 
 
 variable in overall shape and may appear as the 
classic shepherd’s crook or eyebolt, as a U or a 6, or 
coiled, circular, or branched; laboratory techniques, 
such as centrifugation, may be the origin of some of 
these formations. Virions are generally 80 nm in 
diameter with a lipid bilayer anchoring the 
glycoprotein which projects 7 to 10 nm long spikes 
from its surface. They may be 800 nm up to 1,000 nm 
long. In the center of the virion there is a structure 
called nucleocapsid, which is formed by the helically 
wound viral genomic RNA complexed with the 
proteins NP, VP35, VP30, and L. Virally encoded GP 
spikes 10 nm long and 10 nm apart are present on the 
outer  viral envelop of the virion. Between envelope 
and nucleocapsid, the viral proteins VP40 and VP24 
are located [16, 23]. 
 
7. Higher EHF Risk Regions and 
Persons 
      At present all cases of illness or death have 
occurred in central and western Africa. The most 
EHF infected countries of Africa are; Guinea, 
Liberia, Sierra Leone, DRC, Gabon, South Sudan, 
Ivory Coast, Uganda, and South Africa.  Health care 
providers, family members and friends of an infected 
individual are in high risk of EHF infection. 
Mourners who have direct contact with the bodies of 
the deceased as part of burial ceremonies are also in 
high risk of infection of the disease. Hunters in the 
rain forest who come into contact with dead animals 
found lying in the forest are also may infect with 
EVD [47].  
 
8. Diagnosis of EHF 
     Diagnosing EHF in an individual who has been 
infected for only a few days is difficult, because the 
early symptoms, such as red eyes and a skin rash, are 
nonspecific to Ebolavirus infection. When these 
symptoms are seen then the patients are already 
infected with the disease. Doctors may test to rule out 
other diseases like cholera or malaria [8].   
     Diagnostic tests within a few days after symptoms 
begin are; antigen-capture enzyme-linked 
immunosorbent assay (ELISA) testing, IgM ELISA, 
antigen detection tests, serum neutralization test, 
polymerase chain reaction (PCR) and virus 
cultivation and biopsy samples. Later tests in disease 
course or after recovery are; IgM and IgG antibodies. 
Tests in retrospectively in deceased patients are; 
Immunohistochemistry testing, PCR and virus 
isolation. Samples from patients are extreme 
biohazard risk and testing should be conducted under 
maximum biological suppression conditions [8]. 
 
9. Treatment of EHF 
     At present there is no standard treatment for EHF; 
only supportive therapy is available. The preliminary 
treatments are; balancing the patient’s fluids and 
electrolytes, maintaining their oxygen status, blood 
pressure and blood transfusions, and treating them for 
any complicating infections. Current therapy consists 
of maintenance of fluid and electrolyte balance and 
administration of blood and plasma to control 
bleeding. Treatment includes an experimental serum 
that destroys infected cells. Experimental treatment 
has been tested and proven effective in animal 
models but has not yet been used in humans [10].  
     Early recognition of Ebola is important for 
providing appropriate patient care and preventing the 
spread of infection. The infected patient needs to be 
isolated, and immediately contacted needs in local 
and state health departments [43].  
 
10. Prevention of EHF 
     It is still unknown how exactly people are infected 
with EHF, so that prevention of it is more 
challenging. Because it is still unknown how exactly 
people are infected with EHF, there are few 
established primary prevention measures. The best 
way to avoid catching the disease is by not traveling 
to areas where the virus is found. Raising awareness 
among the people about the risk factors for Ebola 
infection and the protective measures individuals can 
take is another way to reduce human infection and 
death. People who have died from EVD should be 
promptly and safely buried [11]. 
     If an outbreak is suspected, the premises should be 
quarantined immediately. Patients, health care 
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providers and family members of the patients should 
use sodium hypochlorite or other detergents during 
washing of hands and other parts of the body to 
inactivate the virus. Regular hand washing is 
necessary after visiting patients in hospital, as well as 
after taking care of patients at home [21]. 
     Burial or incineration of carcasses of animals is 
necessary to reduce the risk of animal-to-human 
transmission of EVD. Banning the movement of 
animals from infected farms to other areas can reduce 
the spread of the disease. Animals infected with 
Ebolavirus should be handled with gloves and other 
appropriate protective clothing and their meat should 
be thoroughly cooked before eating [49]. 
     Health care providers must wear protective 
clothing, such as masks, gloves, full-body hazmat 
suits and goggles; they use infection-control 
measures, such as complete equipment sterilization 
and routine use of disinfectant; isolation of EHF 
patients from contact with unprotected persons when 
the blood or secretions of an infected patient is tested 
and provide treatment to the patients. Rooms of 
infected patients must not be sprayed with 
disinfectant which is dangerous and gives no benefit. 
Infectious waste should be removed periodically 
according to the advice of the EVD specialists [43].  
     Patients that are suspected or confirmed to have 
the disease should be isolated from other patients and 
treated by health workers using strict infection 
control precautions. Several vaccines of Ebolavirus 
are being tested, but none are available for clinical 
use [21].  
 
11. Response by WHO  
     The WHO Strategic Action Plan for Ebola 
Outbreak Response is divided into two parts [43]:  
• Immediate actions to support the three first 
EVD affected countries (Guinea, Liberia, 
and Sierra Leone).  
• Interventions in neighboring at-risk 
countries to increase preparedness and 
prevent the occurrence of additional 
outbreaks.  
     Global Outbreak Alert and Response Network 
(GOARN) support to ongoing outbreak response 
interventions will be scaled-up. Estimated budget for 
response to the epidemic of EHF over 6 months 
(July–December 2014) is given in table 2: 
 
Table 2: Response Plan for WHO and the Governments of Guinea, Sierra Leone and Liberia, July–December 2014: 
Source: [45]. 
 
Item 
 
WHO 
Ebola 
Control 
Center 
Conakry 
WHO 
global 
WHO CO 
Guinea 
 
WHO CO 
Sierra 
Leone 
 
WHO CO 
Liberia 
 
WHO 
CO 
Nigeria 
 
Prepared- 
ness 
neighbor- 
ing 
countries 
Totals 
 
Coordination, finance and 
logistics 
2,224,294 
 
6,036,800 
 
1,132,599 
 
2,626,841 
 
2,180,560 
 
180,000 
 
0 34,722,790 
 
Epidemiology and 
laboratory 
0 6,645,000 
 
102,964 
 
238,804 
 
198,233 
 
180,000 
 
0 16,338,624 
 
Case management and 
infection prevention and 
control; Psychosocial 
support 
0 6,295,000 
 
360,373 
 
835,813 
 
693,815 
 
0 0 26,940,071 
 
Social mobilization/ 
Public Information 
0 1,425,700 
 
102,964 
 
238,804 
 
198,233 
 
360,000 
 
0 2,325,700 
 
Leadership 0 600,000 102,964 238,804 198,233 360,000 0 1,500,000 
Preparedness (Non-
affected countries and 
countries at risk) 
0 900,000 
 
0 0 0 225,000 
 
884,800 
 
2,009,800 
 
Programme Overheads 
7% 
155,701 1,533,175 126,130 292,535 242,835 0 61,936 2,350,376 
Total WHO global plan 
action 
2,379,994 23,435,675 1,927,993 4,471,599 3,711,908 1,305,00
0 
0 37,232,169 
Cost of preparedness 
(potential 8 countries) 
0 0 0 0 0 0 7,573,888 
 
7,573,888 
 
Total WHO response plan 0 0 0 0 0 0 0 44,806,057 
 
12. Situation of 2014 Ebolavirus 
Outbreak in Africa 
      The EHF epidemic was declared in Africa on 21 
March 2014. WHO is committed to support all 
affected countries as well as the neighboring 
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countries to bring the epidemic under control. WHO 
continues to monitor the evolution of the Ebola 
outbreak and engage with all actors from 
governments, technical partners, field operation 
partners, donor partners at local, region, and global 
level. More than 200 experts have been deployed in 
the three countries (Guinea, Liberia, and Sierra 
Leone) by WHO and GOARN partners, but more are 
needed [46, 47]. 
      By 22 August 2014, the WHO, in partnership 
with the Ministries of Health in Guinea, Sierra 
Leone, Liberia, and Nigeria reported 2,615 suspect 
and confirmed cases of EVD, including 1,528 
laboratory-confirmed cases, and 1,427 deaths [11]. 
As of 17 September 2014, WHO and CDC reported a 
total of 5,762 suspected cases and 2,746 deaths 
[12, 50].  
 
12.1 Sierra Leone 
     On 25 May 2014, the Government of Sierra Leone 
(GoSL) through the Ministry of Health and Sanitation 
declared an outbreak of EVD in the country 
following the laboratory confirmation of a suspected 
case from Kailahun district. As of 20 July 2014 a 
total number of 409 cases have been confirmed 
positive for EVD and 139 confirmed deaths in seven 
districts of Sierra Leone (Kambia, Kailahun, 
Kenema, Port Loko, Bo, Bonthe and Western Area) 
but highest in Kailahun (282 Confirmed cases and 97 
Confirmed deaths). The GoSL has been working 
seriously to control the disease but it is spreading 
continuously [20]. 
     By 22 August 2014, the Ministry of Health and 
Sanitation of Sierra Leone and WHO reported a 
cumulative total of 910 suspect and confirmed cases, 
including 804 laboratory-confirmed cases, and 392 
deaths. Cases have been reported from all 12 Sierra 
Leone districts [11]. By 28 August 2014, the Ministry 
of Health and Sanitation of Sierra Leone and WHO 
reported a cumulative total of 1,026 suspect and 
confirmed cases, including 935 laboratory-confirmed 
cases, and 422 deaths [49]. 
     The GoSL with WHO has taken 6 (July to 
December 2014) months of national operational plan. 
The budget of the Government is estimated to be 
$25,817,130. The amount pledged by partners is 
$7,658,180, by the GoSL is $10,00,000 and the 
current gap is $8,258,949 [20]. 
    By 17 September 2014, WHO reported that a total 
of 1,753 suspected cases and 537 deaths in Sierra 
Leone [50]. 
 
12.2 Liberia 
     On 10 April 2014, in Liberia six cases were 
confirmed positive of the Ebolavirus and all died at 
the time. The Ministry of Health and Social Welfare 
(MoHSW) found a case of a Liberian female who is 
married to a Sierra Leonean. She was admitted 
hospital on 23 May, discharged against medical 
advice on 25 May and died six hours later. 
Ebolavirus disease has continued to spread in 7 
counties are; Bomi, Bong, Grand Gedeh, Margibi, 
Montserrrado, Lofa and Nimba (of the 15 counties) 
of Liberia. Six alert counties are; Grand cape Mount, 
Gbarpolu, Grand Bassa, Rivercess, Sinoe and River 
Gee. Up to 24 July 2014, 296 infected were recorded 
with 147 deaths. Already 39 cases have been 
recorded among health workers with 17 deaths [19].  
     By 22 August 2014, the MoHSW of Liberia and 
WHO have reported 1,082 suspect and confirmed 
EVD cases, including 269 laboratory-confirmed, and 
624 deaths. Suspect and confirmed cases have been 
reported in 11 of 15 Counties [11]. By 28 August 
2014, the MoHSW of Liberia and WHO have 
reported 1,378 suspect and confirmed EVD cases, 
including 322 laboratory-confirmed, and 694 deaths 
[49]. 
     By 17 September 2014, WHO reported that a total 
of 3,022 suspected cases and 1,578 deaths in 
Liberia [50]. 
     From onset of the epidemic, a multi-disciplinary 
National Task Force (NTF) chaired by the MoHSW 
was re-activated in March 2014 to ensure effective 
coordination of the response efforts. On 26 July 
2014, the President has declared the EVD epidemic 
as national health emergency and established 
National Task Force [19].   
     Estimated budget for response to the epidemic of 
Ebolavirus haemorrhagic fever over six months (July 
to December 2014). Total estimated budget is 
$21,430,990, pledged by partners is $6,185,830 and 
the gap is $15,245,160 [45]. 
 
12.3 Guinea 
    On 22 March 2014, the Guinea Ministry of Health 
notified WHO about a rapidly outbreak of EVD [48]. 
The WHO Regional Office for Africa organized an 
emergency inter-ministerial meeting in Accra, Ghana, 
on 2–3 July 2014 to enable Member States and 
partners to reach consensus on a regional response 
strategy to halt the epidemic. By 8 July 2014, Guinea 
had recorded 409 cases of Ebolavirus (296 was 
confirmed) and 309 deaths [18].  
     By 22 August 2014, the Guinea Ministry of 
Health announced 607 suspect and confirmed cases 
of EVD, including 443 laboratory-confirmed cases, 
and 406 deaths [11]. By 28 August 2014, the Guinea 
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Ministry of Health announced 648 suspect and 
confirmed cases of EVD, including 482 laboratory-
confirmed cases, and 430 deaths [12]. 
     By 17 September 2014, WHO reported that a total 
of 965 suspected cases and 623 deaths in Guinea 
[50]. 
    The highest pandemic area is Guéckédou where 
166 cases were confirmed and 132 had died. Other 
pandemic areas are Macenta, Kissidougou, Conakry, 
Dabola, Télimélé, Boffa, Dubreka, Djingaraye, Fria, 
Siguiri, Pita, Nzerekore, Yamou and Kouroussa.  
Estimated budget for response to the epidemic of 
Ebolavirus haemorrhagic fever over six months (July 
to December 2014). Total estimated budget is 
$11,131,419, pledged by partners is $714,286 and the 
gap is $10,417,133 [18]. 
 
12.4 Nigeria 
     The first reported Ebola case in Nigeria was an 
imported case of a Liberian-American, Patrick 
Sawyer, who travelled by air from Liberia and 
became violently ill upon arriving in the city of 
Lagos. Sawyer died 5 days later, on 25 July 2014 [2]. 
On 19 August, it was reported that the doctor who 
treated Sawyer, Ameyo Adadevoh, had also died of 
EVD [32]. On 6 August, Nigerian authorities 
confirmed the Ebola death of a nurse who had also 
treated Sawyer [26]. By 22 August 2014, the 
Nigerian Ministry of Health and WHO reported 16 
suspect and confirmed cases, including 12 laboratory-
confirmed, and 5 deaths [11]. 
    By 17 September 2014, WHO reported that a total 
of 21 suspected cases and 8 deaths in Nigeria [50]. 
    Government of Nigeria has announced that it is 
reversing its decision to keep schools closed after the 
summer holiday until 13 October, in order to halt the 
spread of Ebola [49]. 
 
12.4 Senegal 
    On 30 August 2014, Senegal’s Ministry of Public 
Health and Social Affairs provided WHO with details 
about a case of EVD announced in that country on 29 
August. The case is a 21-year-old male native of 
Guinea, who arrived in Dakar, by road, on 20 August 
and stayed with relatives at a home in the outskirts of 
the city. On 23 August, he sought medical care for 
symptoms that included fever, diarrhoea, and 
vomiting. He received treatment for malaria, but did 
not improve and left the facility. On 27 August the 
person has suspected as EVD patient but he has 
escaped from hospital. By 17 September 2014, WHO 
reported that a total of 1 suspected cases and no 
deaths in Senegal [50]. 
 
13. Recommendations 
     Up to redemption of EVD people of different 
countries should avoid nonessential travel to Guinea, 
Liberia, Nigeria and Sierra Leone. The healthy 
citizens of these countries should travel in their own 
countries very carefully.  
      Nonessential staff and visitors should be 
restricted from entering the room of patients with 
suspected EVD. Limit the number of visitors allowed 
access to the patient room who take care of the 
patients and they should immediately after taking 
care of the patients wash hands and other parts of the 
body which come contact with the patients with soap, 
detergent and pure water. All visitors use personal 
protective equipment according to the health care 
facility (HCF) guidance. They should maintain 
adequate distance about 15 m from the infected 
patients. 
     Health care providers should perform hand 
hygiene before and after direct patient care. They 
should wear surgical gloves, non-impermeable gown, 
medical mask and goggles when enter in the patient 
care area. Never reuse syringes or needles and do not 
bend, break or otherwise manipulate used needles by 
hand. Laboratory personnel handling potential EVD 
clinical specimens should wear gown, gloves, and 
special respirators. Post-mortem examinations should 
be performed obeying strictly all the rules for EV 
patients handling.   
     Persons who die of EVD must be handled using 
strong protective clothing and gloves. Dead bodies 
should not be sprayed, washed or embalmed. Only 
trained personnel should handle dead bodies during 
the outbreak. Dead bodies should be wrapped in 
sealed leak-proof material and cremated or buried 
promptly in a sealed casket.  
    People of western Africa should not come contact 
with ill or dead animals (especially primates and 
bats) and avoid eating of bushmeat.  
 
14. Concluding Remarks 
     In this paper we have tried to represent elementary 
ideas about the EVD. Although the outbreak of this 
disease is only in central and western Africa, it may 
spread worldwide if the social consciousness is not 
created and proper treatment is not available. After a 
short period ‘the 2014 outbreak’ will extinct but in 
future if the outbreaks occur then they may be more 
fatal than the present outbreak. Yet there is no proper 
treatment or medicine and vaccine to cure the 
patients. The frequent outbreaks may disconnect the 
people of the effected countries from the rest of the 
world. Invention of medicine of this fatal disease is 
necessary to stop the outbreaks of this disease. WHO 
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and other social welfare organizations should create 
necessary fund for the research of this disease. We 
hope within short time the recovery medicines of this 
disease will invent and people will not suffer from 
this disease.  
 
References 
[1]  Baron, R.C., McCormick, J.B. and Zubeir, O.A., “Ebola Virus 
Disease in Southern Sudan: Hospital Dissemination and 
Intrafamilial Spread”, Bulletin of the World Health Organization, 
.1983. 61(6): 997–1003.  
[2]  BBC News, “Nigeria ‘on Red Alert’ Over Ebola Death in 
Lagos, BBC News”, 26 July 2014. 
[3]  Becker, S., Rinne, C., Hofsass, U., Klenk, H.D. and 
Muhlberger, E. “Interactions of Marburg Virus Nucleocapsid 
Proteins”, Virology, 1998. 249 (2), 406–417. 
[4]  Beniac, D.R., Melito P,L., deVarennes, S.L., Hiebert, S.L., 
Rabb, M.J., Lamboo, L.L., Jones, S.M., and Booth, T.F., “The 
Organisation of Ebola Virus Reveals a Capacity for Extensive, 
Modular Polyploidy”, PLoS One, 2012. 7(1), e29608.  
[5]  Bharat, T.A.M., Noda, T., Riches, J.D., Kraehling, V., 
Kolesnikova, L., Becker, S., Kawaoka, Y.,  and Briggs, J.A.G., 
“Structural Gissection of Ebola Virus and its Assembly 
Determinants Using Cryoelectron Tomography”, PNAS, USA, 
2012. 109 (11): 4275–4280. 
[6]  Bowen, E.T., Lloyd, G., Harris, W.J., Platt, G.S., Baskerville, 
A. and Vella, E.E., “Viral Haemorrhagic Fever in Southern Sudan 
and Northern Zaire”, Preliminary Studies on the Aetiological 
Agent, Lancet, 1977. i: 571–573. 
[7]  CDC, “Known Cases and Outbreaks of Ebola Hemorrhagic 
Fever”, Center for Disease Control and Prevention, US 
Department of Health and Human Services. 2008. 
[8]  CDC,  “Ebola Hemorrhagic Fever Information Packet”, 
Centers for Disease Control and Prevention, US Department of 
Health and Human Services. 2009. 
[9]  CDC, “CDC Urges all US Residents to Avoid None-essential 
Travel to Liberia, Guinea and Sierra Leon Because of an 
Unprecedented Outbreak of Ebola”, CDC, July 31, 2014. 2014a. 
[10]  CDC, “Ebola Hemorrhagic Fever”, US Department of Health 
and Human Services. 2014b. 
[11]  CDC, “Update: 22 August 2014, Ebola Hemorrhagic Fever”, 
Center for Disease Control and Prevention. US Department of 
Health and Human Services. 2014c. 
[12]  CDC, “2014 Ebola Outbreak in West Africa, Update: 17 
September 2014”, Centers for Disease Control and Prevention, US 
Department of Health and Human Services. 2014d. 
[13]  Chepurnov, A.A., Chuev, P., P’Iankov, O.V., Efimova, I.V., 
“The Effect of Some Physical and Chemical Factors on 
Inactivation of the Ebola Virus”, Voprosy Virusologii. 1995, 
40(2):74–76. 
[14]  Colebunders, R. and Borchert M., “Ebola Haemorrhagic 
Fever: A Review”, Journal of Infection, 2000. 40: 16–20. 
[15]  ECDC, “Outbreak of Ebola Virus Disease in West Africa, 
European Centre for Disease Prevention and Control”, Third 
update, 1 August 2014. Stockholm: ECDC; 2014. 
[16]  Feldmann, H.K., “Molecular Biology and Evolution of 
Filoviruses”, Archives of Virology Supplementum, 1993. 7: 81–
100. 
[17]  Feldmann, H.K. and Geisbert, T.W. “Ebola Haemorrhagic 
Fever”, The Lancet, 377(9768): 849–862. 2011. 
[18]  GoG, “Planned Response to the Ebolavirus Disease Epidemic 
in Guinea, Ministry of Health Republic of Guinea”, July–
December 2014. 2014. 
[19]  GoL, “Liberia Operational Plan for Accelerated Response to 
Re-occurrence of Ebola Epidemic”, Ministry of Health and Social 
Welfare, July–December 2014. 2014. 
[20] GoSL, “Sierra Leone Accelerated Ebolavirus Disease 
Outbreak Response”, Government of Sierra Leone, Ministry of 
Health and Sanitation, July–December 2014. 2014. 
[21]  IPAC Guidance, “Infection Prevention and Control Guidance 
for Patients with Suspected or Confirmed Ebola Virus Disease 
(EVD) in Ontario Health Care Settings”, Public Health Ontario. 
2014. 
[22]  Jahrling, P.B., Geisbert, T.W., Dalgard, D.W., Johnson, E.D., 
Hall, W.C. and Peters, C.J. “Preliminary Report: Isolation of Ebola 
Virus from Monkeys Imported to USA”. Lancet, 335(8688): 502–
505. 1990. 
[23] Klenk, H.D. and Feldmann, H., “Ebola and Marburg Viruses: 
Molecular Cellular Biology”, British Library Cataloguing-in-
Publication Data, Garland Science, Horizon Bioscience, 
Wymondhan UK. 2004. 
[24] Kuhn, J.H., Becker, S., Ebihara, H., Geisbert, T.W., Johnson, 
K.M., Kawaoka, Y., Lipkin, W.I., Negredo, A.I., Nichol, S.T., 
Peters, C.J., Tenorio, A., Volchkov, V.E. and Jahrling, P.B., 
“Proposal for a Revised Taxonomy of the Family Filoviridae: 
Classification, Names of Taxa and Viruses, and Virus 
Abbreviations”, Archives of Virology, 155(12): 2083–2103. 2010. 
[25] MacNeil, A.,  Farnon, E.C., Morgan, O.W., Gould, P., 
Boehmer, T.K., Blaney, D.D., Wiersma, P., Tappero, J.W., Nichol, 
S.T., Ksiazek, T.G., and Rollin, P.E., “Filovirus Outbreak 
Detection and Surveillance: Lessons From Bundibugyo”, The 
Journal of Infectious Diseases, 204:S761–S767. 2011. 
[26] Mark, M., “Ebola Outbreak: Nurse who Treated First Victim 
in Nigeria Dies”, The Guardian, 7 August 2014. 2014. 
[27] Mateo, M., Carbonnelle, C., Martinez, M.J., Reynard, O., 
Page, A., Volchkova, V.A. and Volchov, V.E., “Knockdown of 
Ebola Virus VP24 Impairs Viral Nucleocapsid Assembly and 
Prevents Virus Replication”, The Journal of Infectious Diseases, 
204 Suppl 3, S892–S896. 2011. 
[28] Muhlberger, E., Lotfering, B., Klenk, H.D. and Becker, S., 
“Three of the Four Nucleocapsid Proteins of Marburg Virus, NP, 
VP35, and L, are Sufficient to Mediate Replication and 
Transcription of Marburg Virus-specific Monocistronic 
Minigenomes”, Journal of Virology, 72(11): 8756–8764. 1998. 
[29] Muhlberger, E., Weik, M., Volchkov, V.E., Klenk, H.D. and 
Becker, S., “Comparison of the Transcription and Replication 
Strategies of Marburg Virus and Ebola Virus by Using Artificial 
Replication Systems”, Journal of Virology, 73(3): 2333–
2342.1999. 
[30] Nanbo, A., Watanabe, S., Halfmann, P. and Kawaoka, Y., 
“The Spatio-temporal Distribution Dynamics of Ebola Virus 
Proteins and RNA in Infected Cells”, Nature, Scientific Report, 
srep 01206. 2013. 
[31] Public Health Agency of Canada, “Ebola Virus, Pathogen 
Safety Data Sheet–Infectious Substances”, Ottawa: Public Health 
Agency of Canada. 2010. 
[32] Reuters, “Lagos Records Second Ebola Case in Doctor Who 
Treated Victim: Nigeria Health Minister”, 4 August 2014. 2014. 
[33] Rollin, P.E., Williams, R.J., Bressler, D.S., Pearson, S., 
Cottingham, M., Pucak, G., Sanchez, A., Trapper, S.G., Peters, 
R.L., Greer, P.W., Zaki, S., Demarcus, T., Hendricks, K., Kelly, 
M., Simpson, D., Geisbert, T.W., Jahrling. P.B., Peters, C.J., and 
Kssiazek, T.G., “Ebola (subtype Reston) Virus among Quarantined 
Nonhuman Primates Recently Imported from the Philippines to the 
United States”, The Journal of Infectious Diseases, 179(suppl 1): 
S108–S114. 1999. 
[34] Sanchez, A., Trappier, S.G., Mahy, B.W.J., Peters, C.J. and 
Nichol, S.T., “The Virion Glycoproteins of Ebolaviruses are 
Encoded in Two Reading Frames and are Expressed through 
Transcriptional Editing”,  Proceedings of the National Academy of 
Sciences (PNAS), USA 93: 3602–3607. 1996. 
[35] Sanchez, A., Yang, Z., Xu, L., Nabel, G.J., Crews, T. and 
Peters, C.J. “Biochemical Analysis of the Secreted and Virion 
10 
 
Glycoproteins of Ebolavirus”, Journal of Virology, 72: 6442–6447. 
1998. 
[36] Sullivan, N., Yang, Z.Y. and Nabel, G.J., “Ebola Virus 
Pathogenesis: Implications for Vaccines and Therapies”, Journal 
of Virology, 77(18): 9733–9737. 2003. 
[37] Volchkov, V.E., Becker, S., Volchkova, V.A., Ternovoj, 
V.A., Kotov, A.N., Netesov, S.V. and Klenk, H.D. “GP mRNA of 
Ebolavirus is Edited by the Ebolavirus Polymerase and by T7 and 
Vaccinia Virus Polymerases”, Virology, 214: 421–430. 1995. 
[38] Watanabe, S., Takada, A., Watanabe, T., Ito, H., Kida, H. and 
Kawaoka, Y., “Functional Importance of the Coiled-coil of the 
Ebolavirus Glycoprotein”, Journal of Virology, 74: 10194–10201. 
2000. 
[39] Waterman, T., “Ebola Cote D’Ivoire Outbreaks”, Stanford 
University. 1999.    
[40] WHO, “Ebola Hemorrhagic Fever in Sudan, 1976, Report of a 
WHO/International Study Team”, Bulletin of the World Health 
Organization, 56(2): 247–270. 1978a. 
[41] WHO, “Ebola Hemorrhagic Fever in Zaire, 1976, Report of 
an International Commission”, Bulletin of the World Health 
Organization, 56(2): 271–293. 1978b. 
[42] WHO, “End of Ebola Outbreak in Uganda (Press Release)”, 
World Health Organization, 20 February 2008. 2008a. 
[43] WHO, “Interim Infection Control Recommendations for Care 
of Patients with Suspected or Confirmed Filovirus (Ebola, 
Marburg) Hemorrhagic Fever”, DP/EPR/WHO, Geneva March 
2008. 2008b. 
[44] WHO, “Ebola Virus Disease Fact Sheet No. 103”, World 
Health Organization, March 2014. 2014a. 
[45] WHO, “WHO Strategic Action Plan for Ebola Outbreak 
Response”, July–December 2014. 2014b. 
[46] WHO, “WHO Statement on the Meeting of the International 
Health Regulations Emergency Committee Regarding the 2014 
Ebola Outbreak in West Africa”, WHO Statement, 8 August 2014. 
2014c. 
[47] WHO, “Frequently Asked Questions on Ebola Virus Disease”, 
Updated 8 July 2014. 2014d. 
[48] WHO, “Ebola Virus Disease in Guinea–23 March 2014”, 
Geneva: WHO; 2014. 2014e. 
[49] WHO, “Ebola Virus Disease, West Africa–Update 28 August 
2014”, Epidemic & Pandemic Alert and Response (EPR)–
Outbreak News (WHO). 2014f. 
[50] WHO, “Ebola Death Toll Passes 1,900, Says WHO”, BBC 
News 17 September 2014. 2014g. 
[51] Wikipedia (20140, The Free Encyclopedia, 2014 West Africa 
Ebola Virus Outbreak.  
 
 
